Two senators introduced legislation this month aimed at the part of antibiotic development that is hardest to fix with money alone: running the clinical trials that prove a new drug works against infections that are already life-threatening.
The Stop Superbugs Act, introduced Aug. 4 by Senator Maggie Hassan of New Hampshire and Senator Roger Marshall of Kansas, would require the director of the National Institute of Allergy and Infectious Diseases to award a competitive grant supporting a clinical research network on antibiotic resistance. It was read twice and referred to the Senate Health, Education, Labor and Pensions Committee.
It has been introduced only. No hearing has been scheduled, and no vote has been held.
The Trial Problem the Bill Addresses
Antibiotic trials fail on logistics in ways that trials for chronic disease drugs do not.
A patient with a serious drug-resistant infection needs treatment within hours. There is no window in which a research coordinator can screen, consent, and randomize at an unhurried pace, and the physician cannot wait for a resistance profile before starting something. That compresses enrollment into a period measured in hours.
The infections are also scattered. A resistant organism that causes a few hundred cases nationally in a year does not concentrate at any one hospital, so a trial needs many sites standing ready to enroll a patient who may never arrive. Maintaining that readiness across dozens of hospitals is expensive, and the cost falls on a developer whose eventual product will be used sparingly by design.
That last point is the structural oddity of this market. A successful new antibiotic is deliberately held in reserve to slow resistance, so it generates modest revenue. Several companies that won approval for new antibiotics have subsequently entered bankruptcy, which is an unusual outcome for a firm whose product regulators had just cleared as effective.
The bill targets the readiness problem rather than the revenue problem. Its stated objectives include rapid recruitment of trial participants, community-based recruitment outreach, pairing new antibiotics with better diagnostics during trials, and development of patient-reported outcomes, according to reporting by CIDRAP.
The diagnostics pairing is the least obvious and arguably the most consequential. Faster identification of which organism is causing an infection determines who is eligible for a trial in the first place, and the same tests later determine which patients receive the drug in clinical practice.
The Network the Bill Would Fund
The research group at the center of the legislation is a federally supported network that runs multi-site clinical studies on drug-resistant infections and builds the site infrastructure those studies require.
The bill would formally authorize its grant through the National Institutes of Health, which changes its footing from a program funded at agency discretion to one with a statutory basis. Whether that produces more stable funding depends on appropriations, which authorization alone does not guarantee.
A naming inconsistency is worth noting for anyone tracking the bill. The official title refers to the Antibiotic Resistance Leadership Group, while sponsors' press materials and news coverage describe an Antimicrobial Resistance Leadership Group. Both refer to the same network.
The Baseline the Bill Is Measured Against
The scale of the underlying problem comes from federal surveillance rather than from the sponsors.
More than 2.8 million antimicrobial-resistant infections occur in the United States each year and more than 35,000 people die as a result, according to CDC estimates. Adding Clostridioides difficile, which is not typically resistant but is associated with antibiotic use, brings the total above 3 million infections and 48,000 deaths.
Those 2019 estimates remain the agency's most robust national figures. Data gaps during the pandemic left the agency missing information for several pathogens on its threat list in a subsequent report, so the current burden may be higher than the published numbers show.
The bill arrived alongside a Joint Economic Committee report estimating that multidrug-resistant infections in hospital patients cost the U.S. health care system $5.7 billion a year, a figure the report says is likely an underestimate because it excludes follow-up care, out-of-pocket costs, lost work time and reduced productivity.
"We've made incredible progress because of antibiotics, but they're only valuable if they still work," Marshall said in a statement announcing the bill. Hassan framed the shortage of new antibiotics as a national security question as well as a clinical one, warning that the country risks becoming reliant on medications available only from abroad.
Who Carries the Risk and What Households Control
Resistant infections are not evenly distributed, and the highest-risk groups are identifiable.
People receiving cancer chemotherapy, transplant recipients, people with indwelling catheters or ventilators, residents of long-term care facilities, people with cystic fibrosis, and anyone with a prolonged hospital stay face the greatest exposure. So do people who have taken repeated antibiotic courses, which selects for resistant organisms.
The everyday actions that reduce risk are unglamorous and effective. Taking antibiotics only when a clinician prescribes them for a bacterial infection, and completing the course as directed, limits selection pressure. Antibiotics do nothing for colds, most sore throats, and most sinus infections. Nobody should take leftover antibiotics or another person's prescription.
Vaccination reduces antibiotic use by preventing infections that lead to prescriptions, and hand hygiene remains the most effective single measure in health care settings. Patients and families can ask whether a catheter or IV line is still needed, since devices left in place longer than necessary are a common route for infection.
Signs that warrant urgent evaluation include a wound that worsens after starting antibiotics, fever that returns after improving, confusion in an older adult, or rapid breathing and low blood pressure, which can indicate sepsis.
Next is a committee decision. The bill would need a markup to advance, and separate antimicrobial legislation, including the PASTEUR Act, first introduced in 2020, has been reintroduced repeatedly without passage. MedicalDaily will report any committee action.
Key Questions Answered
What would the bill do? Require the director of the National Institute of Allergy and Infectious Diseases to award a competitive grant supporting a clinical research network on antibiotic resistance.
Who introduced it? Senators Maggie Hassan of New Hampshire and Roger Marshall of Kansas, on Aug. 4. It was referred to the Senate Health, Education, Labor and Pensions Committee.
Has it advanced? No. It has only been introduced. No hearing or vote has been scheduled.
Why are antibiotic trials so hard to run? Patients need treatment within hours, leaving almost no time to enroll them, and resistant infections are scattered across many hospitals rather than concentrated at a few.
How large is the problem? More than 2.8 million antimicrobial-resistant infections and more than 35,000 deaths occur in the United States annually, according to CDC estimates.
Would this bill produce new antibiotics? Not directly. It targets clinical trial infrastructure rather than the market conditions that make antibiotic development commercially difficult.
What reduces personal risk? Taking antibiotics only as prescribed for bacterial infections, never using leftover or borrowed prescriptions, staying current on vaccinations, and asking whether catheters or IV lines are still needed during a hospital stay.
